Figure 1.
The existence of B and myeloid common progenitors in clonally related CLL and AML. Somatic mutations and VAFs detected in different FACS-sorted cell fractions from the first (A) and second (B) concurrent CLL/AML case. These mutations were confirmed by WES. (C-D) Somatic mutations in the different sorted subpopulations detected by WES. Venn diagrams showing the numbers and percentages of somatic mutations in the first (C) and second (D) cases, respectively. The mutated genes are listed in supplemental Table 1. (E-F) BIOMED-2 genomic PCR for detection of IgH gene rearrangements in different FACS-sorted subpopulations. The range of product sizes in normal polyclonal background are labeled. The detection of positive peaks was expected between the regions of 310 to 360 bp and 250 to 295 bp. Note that the same IgH gene rearrangements were detected in transitional (CD19+CD33+) and AML (CD19−CD33+CD34−) leukemia cells in the first case (E) and in CLL (CD19+CD34−) and AML (CD19−CD34+CD38+) cells in the second case (F). No amplification was detected in other fractions shown in panels A and B because of the limited amount or the quality of genomic DNA.

The existence of B and myeloid common progenitors in clonally related CLL and AML. Somatic mutations and VAFs detected in different FACS-sorted cell fractions from the first (A) and second (B) concurrent CLL/AML case. These mutations were confirmed by WES. (C-D) Somatic mutations in the different sorted subpopulations detected by WES. Venn diagrams showing the numbers and percentages of somatic mutations in the first (C) and second (D) cases, respectively. The mutated genes are listed in supplemental Table 1. (E-F) BIOMED-2 genomic PCR for detection of IgH gene rearrangements in different FACS-sorted subpopulations. The range of product sizes in normal polyclonal background are labeled. The detection of positive peaks was expected between the regions of 310 to 360 bp and 250 to 295 bp. Note that the same IgH gene rearrangements were detected in transitional (CD19+CD33+) and AML (CD19CD33+CD34) leukemia cells in the first case (E) and in CLL (CD19+CD34) and AML (CD19CD34+CD38+) cells in the second case (F). No amplification was detected in other fractions shown in panels A and B because of the limited amount or the quality of genomic DNA.

Close Modal

or Create an Account

Close Modal
Close Modal